Synthetic Biology’s Major Pain Point: Scale

Mar 13, 2022

11:30am – 12:30pm CT

While there are numerous SynBio startups that have reached unicorn status, many of them haven’t produced a single molecule. Those that have a product can’t successfully scale. In this panel, industry experts break down how both SynBio companies and investors can address this issue to effectively bring new solutions to the market.

Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.

photo of Deepak Dugar
Deepak Dugar

Visolis, Inc.

photo of Julianna LeMieux
Julianna LeMieux

Genetic Engineering & Biotechnology News

photo of Kallie Li
Kallie Li

Debut Biotechnology

photo of Kulika Weizman
Kulika Weizman

Creative Ventures

Primary Access
Music Badge
Platinum Badge
Film Badge
Interactive Badge